Drugs / Tegafur,Gimeracil and Oteracil Porassium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04202484 | Feb 2020 → Feb 2022 | gastric cancer | RenJi Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegafur,Gimeracil and Oteracil Porassium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04202484 ↗ |
| Route | Oral | “Tegafur,Gimeracil and Oteracil Porassium Capsules: 40mg/m2 Bid PO×14d Q3W” NCT04202484 ↗ |